FDA Drug Recalls

Recalls / Class II

Class IID-1083-2022

Product

Transderm Scop (scopolamine) Transdermanl System, 1 mg/ 3 days, 10 (patches) transdermal Systems Multipack, Rx only, MFG: Baxter Healthcare Corp, NDC 10019-553-03

Brand name
Transderm Scop
Generic name
Scopolamine
Active ingredient
Scopolamine
Route
Transdermal
NDCs
10019-008, 10019-553
FDA application
NDA017874
Affected lot / code info
McKesson Medical-Surgical (MMS) is not able to identify the particular lot number received by a particular consignee for the recalled prescription products. Each letter includes the date it was distributed to customers and the dates that impacted product may have been shipped to the customer.

Why it was recalled

cGMP deviations: Temperature abuse

Recalling firm

Firm
Mckesson Medical-Surgical Inc. Corporate Office
Manufacturer
Baxter Healthcare Corporation
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
9954 Maryland Drive, Deep Run Iii Ste. 4000, Richmond, Virginia 23233

Distribution

Quantity
56 cartons/10 patches each
Distribution pattern
USA nationwide.

Timeline

Recall initiated
2022-04-13
FDA classified
2022-06-09
Posted by FDA
2022-06-15
Terminated
2023-11-30
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-1083-2022. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: Transderm Scop · FDA Drug Recalls